Trial Outcomes & Findings for Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) (NCT NCT02152956)
NCT ID: NCT02152956
Last Updated: 2024-01-30
Results Overview
Proportion of patients achieving a best response of CR (morphologic CR \[mCR\], cytogenetic CR \[CRc\], molecular CR \[CRm\], or CRh per Interworking Group AML response criteria. CR is defined as mCR, CRc, CRm or CRh. mCR is defined as: normal. neutrophil and platelet counts, less than 5% blast cells in a bone marrow (BM) smear and. no extramedullary disease. CRc is defined as: CR with no evidence of cytogenetic abnormalities in the bone marrow. CRm is defined as: CR with no evidence of molecular abnormalities in the bone marrow. CRh is defined as: CR with partial hematologic recovery.
Recruitment status
TERMINATED
Study phase
PHASE1/PHASE2
Target enrollment
244 participants
Primary outcome timeframe
up to 14 months
Results posted on
2024-01-30
Participant Flow
Participant milestones
| Measure |
Cohort 0-a
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose:
|
Cohort 2a
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose
|
Cohort 3
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after lead-in dose:
|
Cohort 6
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 8
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
1
|
4
|
5
|
4
|
3
|
4
|
6
|
6
|
6
|
5
|
3
|
185
|
12
|
|
Overall Study
COMPLETED
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
1
|
4
|
4
|
4
|
3
|
4
|
6
|
6
|
6
|
5
|
3
|
185
|
12
|
Reasons for withdrawal
| Measure |
Cohort 0-a
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose:
|
Cohort 2a
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose
|
Cohort 3
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after lead-in dose:
|
Cohort 6
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 8
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
Adverse Event
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
0
|
|
Overall Study
Death
|
0
|
3
|
3
|
4
|
1
|
2
|
6
|
6
|
4
|
5
|
3
|
143
|
12
|
|
Overall Study
Lost to Follow-up
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
0
|
|
Overall Study
Withdrawal by Subject
|
1
|
0
|
1
|
0
|
2
|
2
|
0
|
0
|
1
|
0
|
0
|
4
|
0
|
|
Overall Study
Physician Decision
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
Overall Study
Study terminated by sponsor
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
29
|
0
|
|
Overall Study
progressive disease
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
1
|
0
|
Baseline Characteristics
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)
Baseline characteristics by cohort
| Measure |
Cohort 0-a
n=1 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
n=4 Participants
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
n=5 Participants
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
n=4 Participants
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
n=3 Participants
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
n=4 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
n=6 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
n=6 Participants
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
n=6 Participants
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
n=5 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 8
n=3 Participants
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
n=185 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
n=12 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
Total
n=244 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
52 years
STANDARD_DEVIATION NA • n=99 Participants
|
59.3 years
STANDARD_DEVIATION 21.28 • n=107 Participants
|
56.4 years
STANDARD_DEVIATION 17.10 • n=206 Participants
|
71.8 years
STANDARD_DEVIATION 16.54 • n=7 Participants
|
58.3 years
STANDARD_DEVIATION 14.50 • n=31 Participants
|
67.3 years
STANDARD_DEVIATION 11.64 • n=30 Participants
|
53.0 years
STANDARD_DEVIATION 11.33 • n=3 Participants
|
73.5 years
STANDARD_DEVIATION 5.92 • n=6 Participants
|
64.0 years
STANDARD_DEVIATION 10.81 • n=114 Participants
|
61.2 years
STANDARD_DEVIATION 20.17
|
70.0 years
STANDARD_DEVIATION 8.19 • n=19 Participants
|
58.3 years
STANDARD_DEVIATION 14.29 • n=4 Participants
|
65.7 years
STANDARD_DEVIATION 12.02 • n=7 Participants
|
59.5 years
STANDARD_DEVIATION 14.36 • n=7 Participants
|
|
Age, Customized
18 - 65
|
1 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
2 Participants
n=31 Participants
|
2 Participants
n=30 Participants
|
5 Participants
n=3 Participants
|
1 Participants
n=6 Participants
|
3 Participants
n=114 Participants
|
2 Participants
|
1 Participants
n=19 Participants
|
121 Participants
n=4 Participants
|
6 Participants
n=7 Participants
|
151 Participants
n=7 Participants
|
|
Age, Customized
66 - 75
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=31 Participants
|
1 Participants
n=30 Participants
|
1 Participants
n=3 Participants
|
2 Participants
n=6 Participants
|
2 Participants
n=114 Participants
|
2 Participants
|
1 Participants
n=19 Participants
|
53 Participants
n=4 Participants
|
3 Participants
n=7 Participants
|
69 Participants
n=7 Participants
|
|
Age, Customized
>75
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
2 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
1 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
3 Participants
n=6 Participants
|
1 Participants
n=114 Participants
|
1 Participants
|
1 Participants
n=19 Participants
|
11 Participants
n=4 Participants
|
3 Participants
n=7 Participants
|
24 Participants
n=7 Participants
|
|
Sex: Female, Male
Female
|
0 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
4 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
4 Participants
n=3 Participants
|
3 Participants
n=6 Participants
|
2 Participants
n=114 Participants
|
2 Participants
|
0 Participants
n=19 Participants
|
85 Participants
n=4 Participants
|
4 Participants
n=7 Participants
|
109 Participants
n=7 Participants
|
|
Sex: Female, Male
Male
|
1 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
3 Participants
n=31 Participants
|
4 Participants
n=30 Participants
|
2 Participants
n=3 Participants
|
3 Participants
n=6 Participants
|
4 Participants
n=114 Participants
|
3 Participants
|
3 Participants
n=19 Participants
|
100 Participants
n=4 Participants
|
8 Participants
n=7 Participants
|
135 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
0 Participants
|
0 Participants
n=19 Participants
|
15 Participants
n=4 Participants
|
0 Participants
n=7 Participants
|
15 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
1 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
5 Participants
n=206 Participants
|
4 Participants
n=7 Participants
|
3 Participants
n=31 Participants
|
2 Participants
n=30 Participants
|
6 Participants
n=3 Participants
|
6 Participants
n=6 Participants
|
6 Participants
n=114 Participants
|
5 Participants
|
2 Participants
n=19 Participants
|
145 Participants
n=4 Participants
|
12 Participants
n=7 Participants
|
200 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
2 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
0 Participants
|
1 Participants
n=19 Participants
|
25 Participants
n=4 Participants
|
0 Participants
n=7 Participants
|
29 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
Asian
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
0 Participants
|
0 Participants
n=19 Participants
|
12 Participants
n=4 Participants
|
0 Participants
n=7 Participants
|
12 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
2 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
2 Participants
n=114 Participants
|
0 Participants
|
0 Participants
n=19 Participants
|
14 Participants
n=4 Participants
|
3 Participants
n=7 Participants
|
22 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
White
|
1 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
5 Participants
n=206 Participants
|
3 Participants
n=7 Participants
|
3 Participants
n=31 Participants
|
3 Participants
n=30 Participants
|
4 Participants
n=3 Participants
|
6 Participants
n=6 Participants
|
4 Participants
n=114 Participants
|
5 Participants
|
3 Participants
n=19 Participants
|
133 Participants
n=4 Participants
|
9 Participants
n=7 Participants
|
183 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
0 Participants
|
0 Participants
n=19 Participants
|
21 Participants
n=4 Participants
|
0 Participants
n=7 Participants
|
21 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
Other
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
1 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
0 Participants
|
0 Participants
n=19 Participants
|
5 Participants
n=4 Participants
|
0 Participants
n=7 Participants
|
6 Participants
n=7 Participants
|
|
Region of Enrollment
Netherlands
|
0 participants
n=99 Participants
|
0 participants
n=107 Participants
|
0 participants
n=206 Participants
|
0 participants
n=7 Participants
|
0 participants
n=31 Participants
|
0 participants
n=30 Participants
|
0 participants
n=3 Participants
|
0 participants
n=6 Participants
|
0 participants
n=114 Participants
|
0 participants
|
1 participants
n=19 Participants
|
9 participants
n=4 Participants
|
0 participants
n=7 Participants
|
10 participants
n=7 Participants
|
|
Region of Enrollment
United States
|
1 participants
n=99 Participants
|
4 participants
n=107 Participants
|
5 participants
n=206 Participants
|
4 participants
n=7 Participants
|
3 participants
n=31 Participants
|
4 participants
n=30 Participants
|
4 participants
n=3 Participants
|
4 participants
n=6 Participants
|
5 participants
n=114 Participants
|
3 participants
|
1 participants
n=19 Participants
|
120 participants
n=4 Participants
|
12 participants
n=7 Participants
|
170 participants
n=7 Participants
|
|
Region of Enrollment
Italy
|
0 participants
n=99 Participants
|
0 participants
n=107 Participants
|
0 participants
n=206 Participants
|
0 participants
n=7 Participants
|
0 participants
n=31 Participants
|
0 participants
n=30 Participants
|
2 participants
n=3 Participants
|
0 participants
n=6 Participants
|
0 participants
n=114 Participants
|
1 participants
|
1 participants
n=19 Participants
|
8 participants
n=4 Participants
|
0 participants
n=7 Participants
|
12 participants
n=7 Participants
|
|
Region of Enrollment
United Kingdom
|
0 participants
n=99 Participants
|
0 participants
n=107 Participants
|
0 participants
n=206 Participants
|
0 participants
n=7 Participants
|
0 participants
n=31 Participants
|
0 participants
n=30 Participants
|
0 participants
n=3 Participants
|
0 participants
n=6 Participants
|
0 participants
n=114 Participants
|
0 participants
|
0 participants
n=19 Participants
|
5 participants
n=4 Participants
|
0 participants
n=7 Participants
|
5 participants
n=7 Participants
|
|
Region of Enrollment
France
|
0 participants
n=99 Participants
|
0 participants
n=107 Participants
|
0 participants
n=206 Participants
|
0 participants
n=7 Participants
|
0 participants
n=31 Participants
|
0 participants
n=30 Participants
|
0 participants
n=3 Participants
|
1 participants
n=6 Participants
|
0 participants
n=114 Participants
|
1 participants
|
0 participants
n=19 Participants
|
26 participants
n=4 Participants
|
0 participants
n=7 Participants
|
28 participants
n=7 Participants
|
|
Region of Enrollment
Germany
|
0 participants
n=99 Participants
|
0 participants
n=107 Participants
|
0 participants
n=206 Participants
|
0 participants
n=7 Participants
|
0 participants
n=31 Participants
|
0 participants
n=30 Participants
|
0 participants
n=3 Participants
|
1 participants
n=6 Participants
|
1 participants
n=114 Participants
|
0 participants
|
0 participants
n=19 Participants
|
15 participants
n=4 Participants
|
0 participants
n=7 Participants
|
17 participants
n=7 Participants
|
|
Region of Enrollment
Spain
|
0 participants
n=99 Participants
|
0 participants
n=107 Participants
|
0 participants
n=206 Participants
|
0 participants
n=7 Participants
|
0 participants
n=31 Participants
|
0 participants
n=30 Participants
|
0 participants
n=3 Participants
|
0 participants
n=6 Participants
|
0 participants
n=114 Participants
|
0 participants
|
0 participants
n=19 Participants
|
2 participants
n=4 Participants
|
0 participants
n=7 Participants
|
2 participants
n=7 Participants
|
PRIMARY outcome
Timeframe: up to 14 monthsProportion of patients achieving a best response of CR (morphologic CR \[mCR\], cytogenetic CR \[CRc\], molecular CR \[CRm\], or CRh per Interworking Group AML response criteria. CR is defined as mCR, CRc, CRm or CRh. mCR is defined as: normal. neutrophil and platelet counts, less than 5% blast cells in a bone marrow (BM) smear and. no extramedullary disease. CRc is defined as: CR with no evidence of cytogenetic abnormalities in the bone marrow. CRm is defined as: CR with no evidence of molecular abnormalities in the bone marrow. CRh is defined as: CR with partial hematologic recovery.
Outcome measures
| Measure |
Cohort 0-a
n=1 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
n=4 Participants
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
n=5 Participants
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
n=4 Participants
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
n=3 Participants
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
n=4 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
n=6 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
n=6 Participants
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
n=6 Participants
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
n=5 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
n=3 Participants
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
n=185 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
n=12 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Efficacy Based on CR or CRh Rate
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
16 Participants
|
4 Participants
|
SECONDARY outcome
Timeframe: up to 14 monthsRate of CR + CRh + CRi (CR with incomplete blood cell recovery \[CR with incomplete neutrophil {CRn}or platelet recovery {CRp}\]) + MLFS (morphologic leukemia-free state)
Outcome measures
| Measure |
Cohort 0-a
n=1 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
n=4 Participants
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
n=5 Participants
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
n=4 Participants
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
n=3 Participants
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
n=4 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
n=6 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
n=6 Participants
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
n=6 Participants
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
n=5 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
n=3 Participants
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
n=185 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
n=12 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Complete Response Rate
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
27 Participants
|
4 Participants
|
SECONDARY outcome
Timeframe: up to 14 monthsProportion of patients achieving a best response of CR (morphologic CR \[mCR\], cytogenetic CR \[CRc\], or molecular CR \[CRm\] per Interworking Group AML response criteria. CR is defined as mCR, CRc, CRm or CRh. mCR is defined as: normal. neutrophil and platelet counts, less than 5% blast cells in a bone marrow (BM) smear and. no extramedullary disease. CRc is defined as: CR with no evidence of cytogenetic abnormalities in the bone marrow. CRm is defined as: CR with no evidence of molecular abnormalities in the bone marrow. CRh is defined as: CR with partial hematologic recovery.
Outcome measures
| Measure |
Cohort 0-a
n=1 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
n=4 Participants
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
n=5 Participants
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
n=4 Participants
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
n=3 Participants
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
n=4 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
n=6 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
n=6 Participants
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
n=6 Participants
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
n=5 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
n=3 Participants
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
n=185 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
n=12 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
CR Rate
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
13 Participants
|
2 Participants
|
SECONDARY outcome
Timeframe: up to 14 monthsProportion of patients achieving a best response of CRh per Interworking Group AML response criteria. CRh is defined as: CR with partial hematologic recovery.
Outcome measures
| Measure |
Cohort 0-a
n=14 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
n=4 Participants
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
n=5 Participants
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
n=4 Participants
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
n=3 Participants
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
n=4 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
n=6 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
n=6 Participants
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
n=6 Participants
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
n=5 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
n=3 Participants
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
n=185 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
n=12 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
CRh Rate
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
2 Participants
|
SECONDARY outcome
Timeframe: up to 14 monthsProportion of patients achieving a best response of CR, CRh, CRi, MLFS or partial response per Interworking Group AML response criteria. CR is defined as mCR, CRc, CRm or CRh. mCR is defined as: normal. neutrophil and platelet counts, less than 5% blast cells in a bone marrow (BM) smear and. no extramedullary disease. CRc is defined as: CR with no evidence of cytogenetic abnormalities in the bone marrow. CRm is defined as: CR with no evidence of molecular abnormalities in the bone marrow. CRh is defined as: CR with partial hematologic recovery.
Outcome measures
| Measure |
Cohort 0-a
n=1 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
n=4 Participants
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
n=5 Participants
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
n=4 Participants
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
n=3 Participants
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
n=4 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
n=6 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
n=6 Participants
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
n=6 Participants
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
n=5 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
n=3 Participants
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
n=185 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
n=12 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Response Rate
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
35 Participants
|
4 Participants
|
SECONDARY outcome
Timeframe: up to 8 monthsRate of successful hematopoietic stem cell transplantation (HSCT) after the start flotetuzumab treatment and before subsequent therapy.
Outcome measures
| Measure |
Cohort 0-a
n=1 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
n=4 Participants
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
n=5 Participants
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
n=4 Participants
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
n=3 Participants
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
n=4 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
n=6 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
n=6 Participants
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
n=6 Participants
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
n=5 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
n=3 Participants
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
n=185 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
n=12 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
HSCT Rate
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
10 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: Cycle 1 of a 28 day cycle.Population: DLT were reported for dose escalation cohorts only (cohort 0-8)
Maximum Tolerated Dose/Schedule: the MTDS is defined as the highest dose/schedule administered during any Cohort in the study at which the incidence of DLT is \< 33% during the first cycle of MGD006 treatment.
Outcome measures
| Measure |
Cohort 0-a
n=1 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
n=4 Participants
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
n=5 Participants
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
n=4 Participants
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
n=3 Participants
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
n=4 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
n=6 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
n=6 Participants
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
n=6 Participants
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
n=5 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
n=3 Participants
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Occurrence of Dose Limiting Toxicity
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: up to 9 monthsCycle 1 through end of treatment
Outcome measures
| Measure |
Cohort 0-a
n=1 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
n=4 Participants
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
n=5 Participants
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
n=4 Participants
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
n=3 Participants
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
n=4 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
n=6 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
n=6 Participants
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
n=6 Participants
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
n=5 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
n=3 Participants
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
n=185 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
n=12 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Occurrence of Adverse Events (AEs)
|
1 Participants
|
4 Participants
|
5 Participants
|
4 Participants
|
3 Participants
|
4 Participants
|
6 Participants
|
6 Participants
|
6 Participants
|
5 Participants
|
3 Participants
|
185 Participants
|
12 Participants
|
SECONDARY outcome
Timeframe: up to 9 monthsOutcome measures
| Measure |
Cohort 0-a
n=1 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
n=4 Participants
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
n=5 Participants
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
n=4 Participants
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
n=3 Participants
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
n=4 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
n=6 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
n=6 Participants
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
n=6 Participants
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
n=5 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
n=3 Participants
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
n=185 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
n=12 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Occurrence of Serious Adverse Events (SAEs)
|
0 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
1 Participants
|
2 Participants
|
2 Participants
|
1 Participants
|
0 Participants
|
3 Participants
|
1 Participants
|
100 Participants
|
6 Participants
|
SECONDARY outcome
Timeframe: Study Day 1, then every 28 days through 28-days after the last dose (up to 8 months)Population: Participants were analyzed for the development of ADA regardless of dose level. Presence or absence of ADA is not related to dose level. The relevant information is the change from one status (positive, negative, or not tested) to a different status.
Occurrence of anti-drug antibody
Outcome measures
| Measure |
Cohort 0-a
n=244 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Participants With Anti-drug Antibodies
Negative at baseline, not tested on study
|
25 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Participants With Anti-drug Antibodies
Negative at baseline, all negative on study
|
70 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Participants With Anti-drug Antibodies
Negative at baseline, at least 1 positive on study
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Participants With Anti-drug Antibodies
Positive at baseline, not tested on study
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Participants With Anti-drug Antibodies
Positive at baseline, all negative on study
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Participants With Anti-drug Antibodies
Positive at baseline, at least 1 positive on study
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Participants With Anti-drug Antibodies
Not tested at baseline, not tested on study
|
144 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Participants With Anti-drug Antibodies
Not tested at baseline, all negative on study
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Participants With Anti-drug Antibodies
Not tested at baseline, at least 1 positive on study
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: During study drug administration (up to 8 months)Determine safety and efficacy of tocilizumab in the treatment of IRR/CRS as measured by incidence of IRR/CRS
Outcome measures
| Measure |
Cohort 0-a
n=1 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
n=4 Participants
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
n=5 Participants
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
n=4 Participants
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
n=3 Participants
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
n=4 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
n=6 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
n=6 Participants
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
n=6 Participants
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
n=5 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
n=3 Participants
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
n=185 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
n=12 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Patients With Infusion Related Reaction (IRR)
|
1 Participants
|
3 Participants
|
3 Participants
|
3 Participants
|
3 Participants
|
3 Participants
|
5 Participants
|
6 Participants
|
5 Participants
|
5 Participants
|
2 Participants
|
78 Participants
|
8 Participants
|
SECONDARY outcome
Timeframe: up to 9 monthsOutcome measures
| Measure |
Cohort 0-a
n=1 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
n=4 Participants
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
n=5 Participants
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
n=4 Participants
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
n=3 Participants
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
n=4 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
n=6 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
n=6 Participants
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
n=6 Participants
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
n=5 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
n=3 Participants
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
n=185 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
n=12 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Patients With Cytokine Release Syndrome (CRS)
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
107 Participants
|
4 Participants
|
SECONDARY outcome
Timeframe: Study day 1, then every 28 days and 28 days after the last dose (up to 8 months)Population: The PK analysis was conducted for patients receiving 10, 30, 100, 300, and 500 ng/kg/day. The study drug was administered as continuous IV dosing. Due to the short half-life, Cmax is not influenced by drug administration schedule. The data for all participants treated at a dose, regardless of schedule, were analyzed together. Specimens were collected and individually analyzed for concentrations only in the 700 ng/kg/day, no PK parameters were derived for this dose group.
Measure the pharmacokinetics (PK) of flotetuzumab
Outcome measures
| Measure |
Cohort 0-a
n=4 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
n=5 Participants
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
n=4 Participants
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
n=9 Participants
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
n=212 Participants
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Maximum Serum Concentration of Flotetuzumab
|
16.1 pg/mL
Interval 5.55 to 25.3
|
34.5 pg/mL
Interval 21.0 to 55.0
|
82.8 pg/mL
Interval 68.2 to 180.0
|
177 pg/mL
Interval 43.6 to 998.0
|
185 pg/mL
Interval 51.8 to 754.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: 56 daysPopulation: No data was collected regarding transfusion dependency status at baseline or post-baseline.
The number of patients who were transfusion-dependent at baseline and did not receive transfusions during any consecutive 56-day period will be calculated. The number of patients who are transfusion independent at baseline and remain independent during any 56-day post-baseline period will also be calculated.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 6 monthsOutcome measures
| Measure |
Cohort 0-a
n=1 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
n=4 Participants
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
n=5 Participants
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
n=4 Participants
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
n=3 Participants
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
n=4 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
n=6 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
n=6 Participants
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
n=6 Participants
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
n=5 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
n=3 Participants
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
n=185 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
n=12 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Patients Alive at 6 Months
|
1 Participants
|
2 Participants
|
2 Participants
|
3 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
2 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
42 Participants
|
6 Participants
|
SECONDARY outcome
Timeframe: Up to 2 yearsTime from the first dose of study drug until date of evidence of primary refractory disease to flotetuzumab, relapse from CR, CRh or CRi, or death from any cause, whichever occurs first.
Outcome measures
| Measure |
Cohort 0-a
n=1 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
n=4 Participants
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
n=5 Participants
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
n=4 Participants
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
n=3 Participants
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
n=4 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
n=6 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
n=6 Participants
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
n=6 Participants
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
n=5 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
n=3 Participants
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
n=185 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
n=12 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Event-free Survival
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
SECONDARY outcome
Timeframe: Throughout the study, up to 3 years.number of deaths from any cause within 30, 60, 90, or 180 days of first dose of study drug
Outcome measures
| Measure |
Cohort 0-a
n=1 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
n=4 Participants
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
n=5 Participants
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
n=4 Participants
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
n=3 Participants
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
n=4 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
n=6 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
n=6 Participants
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
n=6 Participants
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
n=5 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
n=3 Participants
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
n=185 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
n=12 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mortality Rate
Mortality at 0-30 days
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
23 Participants
|
2 Participants
|
|
Mortality Rate
Mortality at 31-60 days
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
34 Participants
|
3 Participants
|
|
Mortality Rate
Mortality at 61-90 days
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
19 Participants
|
1 Participants
|
|
Mortality Rate
Mortality at 91- >180 days
|
1 Participants
|
2 Participants
|
2 Participants
|
4 Participants
|
0 Participants
|
1 Participants
|
4 Participants
|
4 Participants
|
4 Participants
|
2 Participants
|
1 Participants
|
67 Participants
|
6 Participants
|
|
Mortality Rate
unknown
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
42 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: 1 yearNumber of patients alive at 1 year from first dose of study drug
Outcome measures
| Measure |
Cohort 0-a
n=1 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
n=4 Participants
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
n=5 Participants
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
n=4 Participants
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
n=4 Participants
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
n=3 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
n=6 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
n=6 Participants
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
n=6 Participants
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
n=5 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
n=3 Participants
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
n=185 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
n=12 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Patients Alive at 12 Months
|
1 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
16 Participants
|
3 Participants
|
SECONDARY outcome
Timeframe: up to 14 monthsTime from first dose of study drug to first CR, CRh, CRi, or MLFS
Outcome measures
| Measure |
Cohort 0-a
n=1 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
n=4 Participants
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
n=5 Participants
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
n=4 Participants
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
n=3 Participants
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
n=43 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
n=6 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
n=6 Participants
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
n=6 Participants
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
n=5 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
n=3 Participants
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
n=185 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
n=12 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Median Time to Response
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
NA months
Not estimable due to an insufficient number of participants with events.
|
SECONDARY outcome
Timeframe: Up to 2 yearsPopulation: Analysis is based on the number of participants who had a CR or CRh as reported in Outcome Measure 1
Time of initial documentation of response to the time of disease relapse or death due to any cause, whichever occurs first.
Outcome measures
| Measure |
Cohort 0-a
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
n=1 Participants
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
n=1 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
n=16 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
n=4 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Duration of Response of Patients With CR or CRh
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
4.0 Months
Standard Deviation NA
There was only 1 response in this cohort.
|
—
|
2.3 Months
Standard Deviation NA
There was only 1 response in this cohort
|
—
|
1.4 Months
Standard Deviation 1.04
|
1.1 Months
Standard Deviation 1.56
|
SECONDARY outcome
Timeframe: Up to 2 yearsTime from first dose to death from any cause
Outcome measures
| Measure |
Cohort 0-a
n=1 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
n=4 Participants
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
n=5 Participants
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
n=4 Participants
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
n=3 Participants
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
n=4 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
n=6 Participants
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
n=6 Participants
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
n=6 Participants
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
n=5 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
n=3 Participants
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
n=185 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
n=12 Participants
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Survival
|
NA months
Standard Deviation NA
Not estimable due to an insufficient number of participants with events.
|
NA months
Standard Deviation NA
Not estimable due to an insufficient number of participants with events.
|
NA months
Standard Deviation NA
Not estimable due to an insufficient number of participants with events.
|
NA months
Standard Deviation NA
Not estimable due to an insufficient number of participants with events.
|
NA months
Standard Deviation NA
Not estimable due to an insufficient number of participants with events.
|
NA months
Standard Deviation NA
Not estimable due to an insufficient number of participants with events.
|
NA months
Standard Deviation NA
Not estimable due to an insufficient number of participants with events.
|
NA months
Standard Deviation NA
Not estimable due to an insufficient number of participants with events.
|
NA months
Standard Deviation NA
Not estimable due to an insufficient number of participants with events.
|
NA months
Standard Deviation NA
Not estimable due to an insufficient number of participants with events.
|
NA months
Standard Deviation NA
Not estimable due to an insufficient number of participants with events.
|
NA months
Standard Deviation NA
Not estimable due to an insufficient number of participants with events.
|
NA months
Standard Deviation NA
Not estimable due to an insufficient number of participants with events.
|
SECONDARY outcome
Timeframe: up to 8 monthsInitial dosing procedures were performed as a hospital inpatient. Incidence rate of hospitalization after discharge from the hospital will be calculated
Outcome measures
| Measure |
Cohort 0-a
n=185 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Rate of Hospitalization for Patients in the Expansion Cohort After Initial Discharge
|
NA Participants
Not estimable due to an insufficient number of participants with events.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: up to 8 monthsDuration of hospitalization will be characterized after discharge from initial dosing will be characterized
Outcome measures
| Measure |
Cohort 0-a
n=185 Participants
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 3
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multistep lead-in dose
|
Cohort 6
Flotetuzumab 300 ng/kg/day, continuous infusion, after multistep lead-in dose
|
Cohort 7
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
Flotetuzumab 700 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose
|
MTD Expansion With Ruxolitinib
Flotetuzumab 500 ng/kg/day, continuous infusion, after multistep lead-in dose Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Duration of Hospitalization for Patients in the Expansion Cohort
|
NA Participants
Not estimable due to an insufficient number of participants with events.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
Adverse Events
Cohort 0-a
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Cohort 0-b
Serious events: 1 serious events
Other events: 4 other events
Deaths: 3 deaths
Cohort 0-c
Serious events: 0 serious events
Other events: 5 other events
Deaths: 3 deaths
Cohort 0-d
Serious events: 2 serious events
Other events: 4 other events
Deaths: 4 deaths
Cohort 1
Serious events: 1 serious events
Other events: 3 other events
Deaths: 2 deaths
Cohort 2
Serious events: 2 serious events
Other events: 4 other events
Deaths: 2 deaths
Cohort 2a
Serious events: 2 serious events
Other events: 6 other events
Deaths: 6 deaths
Cohort 3
Serious events: 1 serious events
Other events: 6 other events
Deaths: 6 deaths
Cohort 6
Serious events: 0 serious events
Other events: 6 other events
Deaths: 5 deaths
Cohort 7
Serious events: 3 serious events
Other events: 5 other events
Deaths: 5 deaths
Cohort 8
Serious events: 1 serious events
Other events: 3 other events
Deaths: 3 deaths
MTD Expansion
Serious events: 100 serious events
Other events: 185 other events
Deaths: 144 deaths
MTD Expansion With Ruxolitinib
Serious events: 6 serious events
Other events: 12 other events
Deaths: 12 deaths
Serious adverse events
| Measure |
Cohort 0-a
n=1 participants at risk
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
n=4 participants at risk
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
n=5 participants at risk
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
n=4 participants at risk
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
n=3 participants at risk
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
n=4 participants at risk
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
n=6 participants at risk
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 3
n=6 participants at risk
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 6
n=6 participants at risk
Flotetuzumab 300 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 7
n=5 participants at risk
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
n=3 participants at risk
Flotetuzumab 700 ng/kg/day, continuous infusion, after lead-in dose
|
MTD Expansion
n=185 participants at risk
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
MTD Expansion With Ruxolitinib
n=12 participants at risk
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dos Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
General disorders
Generalised oedema
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Blood and lymphatic system disorders
Disseminated intravascular coagulation
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
4.9%
9/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Blood and lymphatic system disorders
Febrile bone marrow aplasia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Cardiac disorders
Pericardial effusion
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.6%
3/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.1%
2/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Cardiac disorders
Atrial flutter
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Cardiac disorders
Cardiac arrest
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Cardiac disorders
Cardiac failure
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Cardiac disorders
Left ventricular dysfunction
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Stomatitis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.1%
2/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.1%
2/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.1%
2/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.1%
2/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Enteritis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Enterocolitis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Gastric ileus
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Haematemesis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Haematochezia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Lower gastrointestinal haemorrhage
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Upper gastrointestinal haemorrhage
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
General disorders
Pyrexia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
5.4%
10/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
General disorders
Fatigue
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
2.7%
5/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
General disorders
Oedema peripheral
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
General disorders
Asthenia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
General disorders
Face oedema
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
General disorders
General physical health deterioration
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
General disorders
Localised oedema
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
General disorders
Multiple organ dysfunction syndrome
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Hepatobiliary disorders
Cholecystitis acute
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.1%
2/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Hepatobiliary disorders
Cholecystitis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Hepatobiliary disorders
Hypertransaminasaemia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Immune system disorders
Cytokine release syndrome
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
6.5%
12/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Pneumonia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
3.8%
7/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Sepsis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
3.2%
6/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Epstein-Barr virus infection reactivation
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
2.2%
4/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Pneumonia fungal
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
2.2%
4/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Septic shock
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
2.2%
4/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Bacterial sepsis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.6%
3/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Neutropenic sepsis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Staphylococcal bacteraemia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.6%
3/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
COVID-19 pneumonia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.1%
2/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Cellulitis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.1%
2/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Device related infection
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.1%
2/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Enterocolitis infectious
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.1%
2/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Investigations
Coronavirus test positive
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Bacteraemia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
COVID-19
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Clostridium difficile colitis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Clostridium difficile infection
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Cystitis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Diverticulitis intestinal perforated
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Epstein-Barr viraemia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Escherichia infection
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Herpes simplex reactivation
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Klebsiella sepsis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Necrotising fasciitis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Pneumonia pseudomonal
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Pseudomonal bacteraemia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Pseudomonal sepsis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Investigations
Liver function test increased
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Scedosporium infection
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Streptococcal sepsis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Tooth infection
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Urosepsis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Infections and infestations
Wound infection bacterial
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
4.3%
8/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Injury, poisoning and procedural complications
Accidental overdose
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Injury, poisoning and procedural complications
Subdural haematoma
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Injury, poisoning and procedural complications
Subdural haemorrhage
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Investigations
Weight increased
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.6%
3/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Metabolism and nutrition disorders
Failure to thrive
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Metabolism and nutrition disorders
Gout
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Metabolism and nutrition disorders
Lactic acidosis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.6%
3/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer pain
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Nervous system disorders
Syncope
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.1%
2/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Nervous system disorders
Depressed level of consciousness
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Nervous system disorders
Dizziness
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Nervous system disorders
Haemorrhage intracranial
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Nervous system disorders
Haemorrhagic stroke
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Nervous system disorders
Hypercapnic coma
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Nervous system disorders
Ischaemic stroke
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Nervous system disorders
Seizure
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Nervous system disorders
Subarachnoid haemorrhage
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Product Issues
Device infusion issue
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.1%
2/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.1%
2/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Psychiatric disorders
Mental status changes
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Renal and urinary disorders
Azotaemia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
3.2%
6/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.6%
3/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.6%
3/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Respiratory, thoracic and mediastinal disorders
Laryngeal oedema
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.1%
2/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory distress
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.1%
2/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Respiratory, thoracic and mediastinal disorders
Acute pulmonary oedema
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory distress syndrome
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Surgical and medical procedures
Central venous catheter removal
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Vascular disorders
Hypotension
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
2.2%
4/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Vascular disorders
Capillary leak syndrome
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
1.6%
3/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Vascular disorders
Embolism
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.54%
1/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
Other adverse events
| Measure |
Cohort 0-a
n=1 participants at risk
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-b
n=4 participants at risk
Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-c
n=5 participants at risk
Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off
|
Cohort 0-d
n=4 participants at risk
Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
|
Cohort 1
n=3 participants at risk
Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2
n=4 participants at risk
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 2a
n=6 participants at risk
Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 3
n=6 participants at risk
Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after lead-in dose
|
Cohort 6
n=6 participants at risk
Flotetuzumab 300 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 7
n=5 participants at risk
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
Cohort 8
n=3 participants at risk
Flotetuzumab 700 ng/kg/day, continuous infusion, after lead-in dose
|
MTD Expansion
n=185 participants at risk
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dose
|
MTD Expansion With Ruxolitinib
n=12 participants at risk
Flotetuzumab 500 ng/kg/day, continuous infusion, after lead-in dos Ruxolitinib: Oral inhibitor of JAK kinase
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Investigations
Neutrophil count decreased
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
2/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
9.7%
18/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Blood and lymphatic system disorders
Anaemia
|
100.0%
1/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
100.0%
3/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
2/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
3/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
18.9%
35/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
3/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
40.0%
2/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
18.9%
35/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Blood and lymphatic system disorders
Leukocytosis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
3.8%
7/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
6/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
5.9%
11/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
3/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
15.1%
28/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
66.7%
2/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
12.4%
23/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
2/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
5.9%
11/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Diarrhoea
|
100.0%
1/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
2/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
66.7%
4/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
40.0%
2/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
100.0%
3/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
44.9%
83/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
41.7%
5/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
75.0%
3/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
60.0%
3/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
100.0%
3/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
40.5%
75/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
41.7%
5/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
40.0%
2/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
66.7%
2/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
22.2%
41/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
22.7%
42/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
3/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.5%
38/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
41.7%
5/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Stomatitis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
40.0%
2/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
11.9%
22/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
6.5%
12/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
7.0%
13/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
6.5%
12/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
5.9%
11/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
General disorders
Oedema peripheral
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
2/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
66.7%
4/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
40.0%
2/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
66.7%
2/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
42.7%
79/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
58.3%
7/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
General disorders
Fatigue
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
2/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
40.0%
2/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
66.7%
4/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
23.2%
43/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
General disorders
Pyrexia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
40.0%
2/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
2/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
66.7%
2/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
3/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
3/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
40.0%
2/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
66.7%
2/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
37/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
4/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
General disorders
Chills
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
3/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.6%
16/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
2/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
General disorders
Pain
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
60.0%
3/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.1%
15/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
2/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
General disorders
Asthenia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
40.0%
2/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
3.8%
7/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Immune system disorders
Cytokine release syndrome
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
51.4%
95/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
4/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
75.0%
3/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
60.0%
3/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
75.0%
3/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
100.0%
3/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
75.0%
3/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
83.3%
5/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
100.0%
6/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
83.3%
5/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
100.0%
5/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
37.8%
70/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
66.7%
8/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
5.9%
11/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
18.4%
34/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
3/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
3/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.2%
30/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Investigations
Platelet count decreased
|
100.0%
1/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
2/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
3/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
14.1%
26/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Investigations
White blood cell count decreased
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
3/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
3/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
14.1%
26/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
14.1%
26/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
3/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Investigations
Weight increased
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
13.5%
25/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
40.0%
2/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
9.2%
17/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Investigations
Blood creatinine increased
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.6%
16/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
2/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
66.7%
2/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
3/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
5.9%
11/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Investigations
Blood fibrinogen decreased
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.1%
15/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
2/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
100.0%
3/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
2/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
3/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
100.0%
6/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
3/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
100.0%
5/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
40.0%
74/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
2/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
3/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
30.3%
56/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
24.3%
45/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
2/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
75.0%
3/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
3/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
66.7%
2/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
22.2%
41/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
2/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
66.7%
4/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
3/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
3/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
40.0%
2/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
22.2%
41/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
2/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
2/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
66.7%
4/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
21.1%
39/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
40.0%
2/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
2/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
3/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
14.6%
27/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
2/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
66.7%
2/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
3/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
11.4%
21/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Metabolism and nutrition disorders
Hyperphosphataemia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
7.6%
14/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
2/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Metabolism and nutrition disorders
Fluid retention
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.6%
16/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Metabolism and nutrition disorders
Hypervolaemia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
40.0%
2/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
5.4%
10/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
40.0%
2/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
66.7%
2/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
30.8%
57/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
3/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
66.7%
2/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
15.1%
28/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
14.1%
26/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
12.4%
23/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
11.9%
22/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.1%
15/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Nervous system disorders
Headache
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
28.1%
52/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Nervous system disorders
Dizziness
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
11.9%
22/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
2/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Nervous system disorders
Lethargy
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
7.6%
14/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Psychiatric disorders
Insomnia
|
100.0%
1/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
3/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
17.3%
32/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
2/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
14.1%
26/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
2/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
10.8%
20/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Psychiatric disorders
Depression
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
5.4%
10/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
10.3%
19/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
2/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
7.0%
13/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Renal and urinary disorders
Urinary incontinence
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
5.4%
10/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
26.5%
49/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
3/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
100.0%
1/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
15.1%
28/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
41.7%
5/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
14.1%
26/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
14.1%
26/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
12.4%
23/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Vascular disorders
Hypertension
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
13.0%
24/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
3/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
40.0%
2/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.1%
15/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
6.5%
12/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Skin and subcutaneous tissue disorders
Petechiae
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
18.4%
34/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
13.5%
25/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
13.5%
25/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
2/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
1/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
9.7%
18/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
50.0%
6/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
6.5%
12/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Vascular disorders
Hypotension
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
66.7%
2/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
2/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
33.3%
1/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.5%
38/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
16.7%
2/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Vascular disorders
Flushing
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
20.0%
1/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
25.0%
1/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
7.0%
13/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
8.3%
1/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
|
Vascular disorders
Capillary leak syndrome
|
0.00%
0/1 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/4 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/6 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/5 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/3 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
7.0%
13/185 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
0.00%
0/12 • Throughout the study, up to 95 months.
AEs are based on physical exam, patient reports, and significant abnormal laboratory values. AEs were not collected in survival follow up. Only SAEs were collected in survival follow up if related to study treatment. Only patients who received study treatments were assessed for safety. Progression of cancer causing hospitalization or death is not considered an SAE, unless considered drug-related by the investigator.\[
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: LTE60